GlassScriptPhysician profile
David G Wilding
NPI 1740391226
$5,714.32
in general payments reported to CMS, 2019-2025
37 companies · $959 in 2025
The $959 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $580 · 2021: $927 · 2022: $842 · 2023: $1,027 · 2024: $968 · 2025: $959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,955.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,947.45 | 2019-2025 | Vraylar, Linzess, Creon |
| Amgen INC. | $767.46 | 2019-2025 | Evenity, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $548.42 | 2020-2024 | Xarelto, Spravato |
| Astrazeneca Pharmaceuticals LP | $380.68 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amarin Pharma, INC. | $232.49 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $219.37 | 2021-2023 | |
| Pfizer INC. | $135.93 | 2019-2025 | |
| Insulet Corporation | $135.00 | 2025 | Omnipod |
| Abbott Laboratories | $123.64 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $98.07 | 2020-2025 | Veozah |
| Nestle Healthcare Nutrition INC. | $94.38 | 2020-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.30 | 2024-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $76.85 | 2022 | |
| Phathom Pharmaceuticals, INC. | $73.93 | 2024 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $69.74 | 2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $67.57 | 2019-2024 | |
| Lilly USA, LLC | $65.97 | 2019-2021 | |
| Organon LLC | $59.38 | 2021-2023 | Nexplanon |
| Merck Sharp & Dohme LLC | $55.98 | 2019-2021 | |
| Boston Scientific Corporation | $52.81 | 2020-2024 | Wavewriter Alpha Prime 16 |
| Supernus Pharmaceuticals, INC. | $47.63 | 2019-2022 | |
| Glaxosmithkline, LLC. | $40.23 | 2024 | Trelegy Ellipta |
| Medtronic, INC. | $37.55 | 2022-2025 | Inceptiv |
| E.R. Squibb & Sons, L.L.C. | $35.99 | 2019-2022 | |
| Dexcom, INC. | $34.12 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.87 | 2019-2020 | |
| Axsome Therapeutics, INC. | $26.95 | 2024 | Auvelity |
| Edwards Lifesciences Corporation | $23.90 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Allergan, INC. | $23.19 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $22.81 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $22.43 | 2020 | |
| Inspire Medical Systems, INC. | $18.30 | 2023 | Inspire |
| Esperion Therapeutics, INC. | $15.49 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.87 | 2025 | |
| Sunovion Pharmaceuticals INC. | $13.69 | 2021 | |
| Lundbeck LLC | $13.56 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $13.32 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wilding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.